Background Wilms tumor (WT) is the most common childhood kidney cancer worldwide, yet its incidence and clinical behavior vary according to race and access to adequate healthcare resources. To guide and streamline therapy in the wartorn and resource-constrained city of Baghdad, Iraq, we conducted a first-ever molecular analysis of 20 WT specimens to characterize the biological features of this lethal disease within this challenged population. Methods Next-generation sequencing of ten target genes associated with WT development and treatment resistance (WT1, CTNNB1, WTX, IGF2, CITED1, SIX2, p53, CRABP2, and TOP2A) was completed. Immunohistochemistry was performed for 6 marker proteins of WT (WT1, CTNNB1, NCAM, CITED1, SIX2, and p53). Patient outcomes were compiled. Results Mutations were detected in previously described WT "hot spots" (e.g., WT1 and CTNNB1) as well as novel loci that may be unique to the Iraqi population. Immunohistochemistry showed expression domains most typical of blastemalpredominant WT. Remarkably, despite the challenges facing families and care providers, only one child, with combined WT1 and CTNNB1 mutations, was confirmed dead from disease. Median clinical follow-up was 40.5 months (range 6-78 months). Conclusions These data suggest that WT biology within a population of Iraqi children manifests features both similar to and unique from disease variants in other regions of the world. These observations will help to risk stratify WT patients living in this difficult environment to more or less intensive therapies and to focus treatment on cell-specific targets.
Introduction
Wilms tumor (WT) is the most common childhood kidney cancer worldwide, and its incidence varies with race [1, 2] . Globally, black children of sub-Saharan African ancestry consistently show the highest incidence of WT regardless of nationality, whereas children of Asian descent typically show the lowest rate. However, little has been reported on the incidence, biology, or outcome from WT in the formerly suppressed and currently war-torn Middle Eastern population of Iraqi children. The only report to date describes in limited detail a 51% survival from WT for Iraqi children treated during the height of the second Persian Gulf War [3] . Moreover, no report characterizing WT biology in 1 3 this population has been published. Given the challenges of treating children for any cancer and of studying population-specific outcomes and disease characteristics in the midst of tyranny, war, and terrorism, this limited availability of data documenting WT behavior and biology in Iraq is understandable.
WT is a genetically heterogeneous disease that arises in the setting of specific and consistent "hot spot" alterations in predisposing genetic loci, which theoretically could vary with race and, therefore, drive the observed disparate incidences. Specifically, mutations in WT1, CTNNB1, WTX (i.e., AMER1), and IGF2 have been shown to occur relatively commonly in WT, and have been implicated as the initial hits promoting the WT sequence [4] [5] [6] . Perturbations in the expression of specific gene products, such as CITED1, SIX2, and NCAM, have been reported to label self-renewing blastema, the putative WT cancer stem cell, and malignant analogue of the multipotent nephron progenitor [7] [8] [9] [10] [11] . In addition, TOP2A and CRABP2 were detected abundantly in our recent proteomic analysis of 98 WT specimens from North America and Kenya, and each is a targetable moiety specific to WT biology (e.g., etoposide and cis-all trans retinoic acid, respectively) [12] . Finally, two other genes, p53 and MYC-N, have been shown to mutate or gain copy number, respectively, in treatmentresistant anaplastic WT [13] [14] [15] . These genes and protein products form the basis of this targeted molecular analysis to assess similarities and differences in biological characteristics between Iraqi WT and specimens of the Western world.
While the developed countries have shifted therapeutic protocols to stratify patients according to biologic risk groups, little data have been published on WT outcomes or biology from the once suppressed and now war-ravaged Iraqi population. We designed these studies to characterize the biology and clinical behavior of WT arising in Iraqi children as an initial means to streamline delivery of care under currently volatile conditions.
Methods
To help steer risk assignment in future therapeutic algorithms in this politically unstable region of Baghdad, Iraq, we examined the biologic composition of WT treated there. We performed a next-generation sequencing (NGS) analysis targeting ten genes associated with Wilms tumorigenesis and disease progression along with an immunohistochemical (IHC) evaluation of six proteins also relevant to WT biology, as introduced above. Approval to conduct these studies was provided through the Vanderbilt University Institutional Review Board (#100734 and #020888).
WT cohort from Baghdad, Iraq
All patients with kidney tumor (n = 154) who were treated at the Children's Welfare Teaching Hospital (CWTH) in Baghdad, Iraq, between June 2008 and March 2014 were selected for potential molecular evaluation. Multiple formalin-fixed paraffin-embedded (FFPE) tissue blocks archived from 35 patients could be located, and all were shipped from CWTH to the Vanderbilt Children's Hospital (VCH) in Nashville, TN, for analysis. The remaining bulk of patient specimens either had been retained by the families or had been shipped previously to other international collaborators for protective storage given governmental instability. No other storage conditions, such as liquid nitrogen, are available currently to archive fresh tissue specimens in this low-income setting.
After sectioning and hematoxylin and eosin (H&E) staining, a thorough pathologic review was completed at VCH to verify histologic diagnosis and to assure quality of tissue preservation. Detailed review of sections from all shipped tissue blocks (n = 35 patients) yielded the final 20 WT specimens and 4 adjacent kidneys from which a WT arose and that were of sufficient quality for molecular analysis. Excluded blocks from the remaining 15 patients were determined either to carry an alternative diagnosis (e.g., papillary renal cell carcinoma or congenital mesoblastic nephroma) or the tissue was completely necrotic. Demographic variables (e.g., age and stage at diagnosis, gender, time to last follow-up, relapse, and vital status) of these 20 patients were compiled.
Immunohistochemical analysis
To evaluate the expression of proteins that are common to WT and appear fundamental to its biology, the 20 Iraqi WT specimens were examined using immunohistochemistry (IHC) for WT1, CTNNB1, NCAM, CITED1, SIX2, and p53. Briefly, and in accordance with our previously published IHC protocol, 5 μm tissue sections were subjected to antigen retrieval and then probed for each protein at the following dilutions: WT1-1:1000 (Santa Cruz Biotechnology, Dallas, TX), CTNNB1-1:100 (Cell Signaling, Danvers, MA), NCAM-1:100 (Cell Signaling), CITED1-1:50 (Lab Vision, Fremont, CA), SIX2-1:20 (US Biological, Salem, MA), and p53-1:100 (Cell Signaling). Proteins were visualized using the Dako EnVision HRP+ System (Agilent Technologies, Carpinteria, CA) [7, 9, 16] . A pediatric-trained pathologist (RRF) reviewed in a blinded manner all 120 immunostained WT slides to evaluate the expression domain between cellular elements (e.g., blastema and epithelia) and subcellular compartments (e.g., cytosol and nucleus). The presence or absence of protein expression was tabulated.
Next-generation sequence analysis
To explore the biology of Iraqi WT further, genomic DNA was isolated from the 20 WT and 4 adjacent kidney specimens using QIAamp DNA FFPE Tissue kit according to the manufacturer's protocol (Qiagen, Valencia, CA). Briefly, four paraffin sections at 10 μm each were acquired from the highest quality tissue block of each patient (Vanderbilt Translational Pathology Shared Resource). After removal of wax in xylene, tissue sections were digested, and genomic DNA was isolated and purified. To evaluate the presence of mutations in the ten target genes documented previously to promote Wilms tumorigenesis [WT1, CTNNB1, AMER1 (i.e., WTX), and IGF2] or to facilitate treatment resistance and disease maintenance (p53, MYC-N, CITED1, SIX2, CRABP2, and TOP2A), genomic DNA was analyzed using next-generation sequencing (NGS) technology for singlenucleotide variations, insertions, and deletions in these targeted loci. Briefly, multiplex amplicon sequencing libraries were prepared using an amplicon gene primer panel that targeted only coding regions of these ten genes. Input DNA was quantified using the high-sensitivity dsDNA assay on the Qubit fluorometer and normalized to 4 ηg/μL. The multiplex PCR was performed in eight reactions per sample using a custom Qiagen GeneRead DNA-seq Panel following the manufacturer's protocol without deviation (Qiagen).
Data quality control and analysis
Variant calling was performed using the standard Genome Analysis Toolkit Haplotype Caller pipeline (GATK version 3.1-1, http://www.broad insti tute.org/gatk/) [17] . Singlenucleotide variant (SNV) mutation calls were made using the following threshold filters: (1) each had to pass GATK Variant Quality Score Recalibration filtering, (2) DP was greater than 10, (3) genotype quality was greater than 30, (4) SNV was not observed in the adjacent kidneys, and (5) the allele frequency in the 1000 Genomes Project was greater than 0.2%. For small insertions and deletions (Indels), we further manually inspected the alignment and removed calls close to the end of aligned reads. In addition, we used the MuTect software to call SNV mutations further to detect low allele fraction (AF) mutations [18] . Given the low number of available adjacent kidney specimens that could be located, we combined these four as a single sample and ran MuTect of individual tumors against this combined sample. We selected mutation calls with AF greater than 0.1 for further analysis.
Mutation calls are reported for those SNVs occurring only in the WT specimens, and are annotated using ANNO-VAR (version 2014jul14) [19] . Only nonsynonymous SNV mutations with predicted deleteriousness in one of the algorithms implemented in ANNOVAR, and Indel mutations in exonic and UTR regions, are called as potentially functionally significant. This strict approach to mutation calls yielded the greatest possible confidence.
Results

WT cohort
The median follow-up period for this WT cohort was 40.5 months (range 6-78 months), and the frequency of unfavorable histology (UH) was typical for this childhood renal malignancy at 5%. Of the 20 WT patients included in this molecular analysis, only one child is confirmed to have died of progressive disease (Table 1) . That FHWT specimen interestingly contained a mutation in both WT1 and CTNNB1 ( Table 2 ). The initial resection of the primary WT was accomplished for 19 of the 20 patients before administration of chemotherapy. Remarkably, only two patients in this cohort were lost to follow-up (LTFU): one with no evidence of disease and having completed all therapy (presumed alive), and the other who was receiving treatment for local relapse in the nephrectomy bed and subsequently abandoned care (presumed dead). Advanced-stage disease at presentation was prevalent in these 20 Iraqi children, as 9 presented with stage III and 5 with stage IV disease. Relapse rate was typical at 20%.
Immunohistochemistry
The immunohistochemical analysis, probing for the expression of 6 proteins common to WT biology, revealed an expected pattern of detection between cellular elements and subcellular localization when compared with our prior studies ( Fig. 1; Table 1 ) [7-9, 11, 16] . In summary, this cohort of 20 WT specimens showed a significant expression of five markers that label proliferating blastema, the putative WT stem cell. As expected, β-catenin was also detected in the nucleus of a majority of specimens harboring a mutation in this gene (Tables 1, 2 ). Furthermore, p53 was detected diffusely in the single UHWT specimen, which interestingly harbored a dual mutation in exon 4 of this marker of WT treatment resistance [16] .
WT-specific gene mutations
The NGS analysis, targeting ten WT-associated genes that contribute to its tumorigenesis, self-perpetuation, and disease progression, detected a number of both expected and novel mutations that appear to be functionally relevant (Table 2 ). Specific to the four genes commonly analyzed for alterations in WT, WT1 was mutated in four specimens (20%; typical frequency reported in other populations). CTNNB1 was mutated in seven WT specimens (35%; higher frequency than reported in other populations) and in three of the four specimens harboring a WT1 mutation, which is a typical association for these two genes in other series analyzing WT genetic alterations. AMER1 (i.e., WTX) was mutated in three WT specimens (15%; typical frequency). 
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Finally, in the one UHWT, p53 was mutated twice in exon 4 (Table 3 ). Of the remaining six genes that are of interest to different aspects of WT biology, four (SIX2, IGF2, TOP2A, and CITED1) were mutated in a single WT specimen each included in this cohort (frequency of 5% each).
Neither MYC-N nor CRABP2 was found to have a mutation in this analysis.
Discussion
This report is the first to characterize the demographics and biology of a recent WT cohort from the war-torn and resource-constrained city of Baghdad, Iraq. The principal findings from this work suggest that Iraqi children having WT present largely with advanced-stage disease yet within the typical age spectrum, raising concern for a potentially more aggressive biology. NGS was used to investigate for a population-specific biology. A largely expected pattern of alterations in ten WT-associated genes was observed using targeted techniques, while several unique mutations were revealed, as well. Although the follow-up period of slightly more than three years is relatively short for a WT cohort, survival was remarkable. This survival rate approaches that documented in the Western world and improves upon that reported from the CWTH in Baghdad during the 2005-2009 era, which was alarmingly only 51% [3] . Once validated in other Iraqi WT specimens that are being collected prospectively, the results of this NGS analysis may one day guide future therapies to more or less intensive regimens according to patient-and tumor-specific biological criteria. WT biology recapitulates the growth properties of the developing kidney, but shows an imbalance towards progenitor maintenance and symmetric cell division. The Iraqi WTs analyzed in this study commonly showed cellular predominance of blastema, its putative cancer stem cell, and the malignant analogue of the multipotent nephron progenitor in the embryonic metanephric mesenchyme (MM) and an ominous feature of aggressive behavior [25] [26] [27] . Indeed, these Iraqi WT specimens showed robust activation of five markers of WT blastema and MM, which likely accounts for the more commonly advanced stage of disease at presentation. Using strict filters for true mutations in the ten genes analyzed, CTNNB1 showed tumor-specific alterations in 35% of these WT specimens, which is higher than the typical frequency of 15% in Western populations studied. This proto-oncogene was mutated in three of the four specimens also harboring a WT1 alteration, which is an expected association [4, 28, 29] .
The authors acknowledge several limitations with this pilot study that center around the challenges of conducting molecular research on specimens originating from patients being treated in low-income countries. First, the patient and specimen numbers are low due to the significant constraints on resources available to Iraqi physicians to document patient outcomes and to archive WT specimens during the previous suppressive regime and recent war. Incorrect diagnoses and tissue necrosis further contributed to the need to exclude specimens from the final analysis. Furthermore, tumor specimen availability may indicate that a patient was more thoroughly integrated into the Iraqi healthcare system, which might introduce a selection bias to this analysis. Greater adherence and/or follow-up among patients with available tumor specimens could help to explain the excellent survival rates observed in this cohort. Second, loss of heterozygosity (LOH) at 1p and 16q and copy-number gain at 1q have been determined as poor prognostic indicators in multiple series from the Western world, and are used to risk stratify FHWT patients who have had the initial resection of the primary lesion (i.e., have not received neoadjuvant therapy), but these important biological factors could not be assessed rigorously in these current studies given the rare occurrence of these chromosomal aberrations (~ 5% of WT). To address these study limitations and to validate the current findings, plans are underway to optimize patient followup and to expand the molecular analysis to additional Iraqi patients having tissues archived at international institutions or with parents and those being treated prospectively from the time of this study. Table 3 Mutation rate for ten target Wilms tumor (WT)-associated genes *Frequency provided by meta-analysis when available, reported as effect size (95% confidence interval) [20] . For genes not included in the metaanalysis, range of frequencies reported in the literature is provided † Note that the majority of the studies reported here analyzed UHWT only. Overall incidence of p53 mutation in WT is about 5% [24] Genes In conclusion, this seminal study provides an initial glimpse into the biology of WT arising in Baghdad, Iraq, which shares biological features with specimens treated in other regions of the world, yet also carries potentially unique, population-specific characteristics. Although the current conditions in Iraq do not support high-throughput genomic screening to prognosticate WT outcome and to personalize therapy, simple immunohistochemical staining for p53 accumulation, for example, may be a useful starting point to risk stratify potentially treatment-resistant tumors. Nevertheless, efforts to help patients overcome the barriers to health care in a war zone and to personalize therapy according to specific biological factors will one day improve outcomes for these patients living in a significantly challenged environment.
